Sunshine Biopharma prices USD 6 million public offering at USD 0.5 per unit

Sunshine Biopharma Incorporated

Sunshine Biopharma Incorporated

SBFM

0.00
  • Sunshine Biopharma priced a $6 million public offering on a best-efforts basis.
  • The deal comprises 12,000,000 common units or pre-funded units priced at $0.5 per common unit, each paired with two Series C warrants.
  • The Series C warrants carry an initial exercise price of $0.5, are exercisable immediately, and expire five years from issuance.
  • Closing is expected on or about May 19, 2026, with proceeds earmarked for general corporate purposes and working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605181215ACCESSWRNAPR_____1167768) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.